-
Mashup Score: 4
Objectives The Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout (CARES) trial suggested a higher risk of cardiovascular (CV) death from febuxostat than from allopurinol. However, a significant number of patients died after discontinuation of febuxostat or allopurinol. We investigated whether major adverse cardiovascular events (MACE) and CV death were increased because of…
Source: RMD OpenCategories: Latest Headlines, RheumatologyTweet
Check out the findings from the CARES trial on #cardiovascular safety of #allopurinol and #flebuxostat: ▶️ MACE and cardiovascular death increased in gout after discontinuation of #allopurinol or #flebuxostat ▶️ changes in sUA associated with MACE 🔗 https://t.co/pS5njT62Bg https://t.co/cSPlWjvnlf